Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Virginia Borges

Breast Oncology · CU Anschutz Medical Campus

View

Dr. William Gradishar

Breast Oncology · NU

View

Dr. Jame Abraham

Breast Oncology · Cleveland Clinic

View

Dr. Amy Comander

Breast Oncology · PHS

View

Dr. Paolo Tarantino

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Anastasia Martynova

Breast Oncology · USC

View

Dr. Rani Bansal

Breast Oncology · Duke

View

Dr. Gilbert Bader

Breast Oncology · OSUMC

View

Dr. VK Gadi

Breast Oncology · UI Health

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Neoadjuvant Chemotherapy is Associated with Worse 5-Year Overall Survival in Patients with Metaplastic Breast Cancer Compared with Primary Surgery: A National Cancer Database Analysis.

    Aug 20, 2025DOI: 10.1245/s10434-025-18085-zJournal ArticleASO

    Written by: Anna M ChichuraXiaoying ChenMargo NelisLauren KopickyWei WeiAzka AliRahul TendulkarZahraa Al-Hilli

    Find these authors on Roon

    LK

    Dr. Lauren Kopicky

    Breast Surgical Onc · Cleveland Clinic

    AA

    Dr. Azka Ali

    Breast Oncology · Cleveland Clinic Lerner

    Methods

    A retrospective analysis was performed using the National Cancer Database (NCDB), a publicly available database composed of de-identified information collected from over 70% of newly diagnosed cancer cases at any of the 1500 Commission on Cancer-accredited facilities in the United States (US).12 The NCDB was reviewed for patients with stage I–III MpBC diagnosed from 2010 to 2019 who were treated with upfront surgery followed by adjuvant chemotherapy or neoadjuvant systemic therapy followed by surgical resection. Patients with metastatic (stage IV) or non-invasive (stage 0) disease, absent or unknown tumor size, a surgical procedure coded as ‘none’, ‘local tumor destruction only’, ‘not otherwise specified’, or ‘unknown’ were excluded.Patients with unknown or missing survival data were excluded from the survival analysis. Clinicopathologic data were abstracted, including clinical and pathologic T and N categories; ER, PR, and HER2 status; use of neoadjuvant chemotherapeutic agents; use of neoadjuvant immunotherapeutic agents; rate of upfront surgery; type of surgery performed; use of adjuvant chemotherapy; and use of adjuvant radiation. Primary study endpoints included pathologic complete response (pCR) to NACT, rate of breast conservation, and overall survival (OS).Patient characteristics were summarized using descriptive statistics. Continuous variables were reported as median with interquartile range (IQR) and range, while categorical variables were presented as frequencies and percentages. Treatment group comparisons for continuous variables were conducted using the Wilcoxon rank-sum test. Categorical variables were compared using the Chi-square test as well as primary endpoints of complete response and rate of breast conservation. OS was analyzed using the Kaplan–Meier method and differences between treatment groups were assessed using the log-rank test. Multivariable analyses were performed using Cox proportional hazards models for survival outcomes, adjusting for clinically relevant covariates. All statistical tests were two-sided and a p-value < 0.05 was considered statistically significant. Statistical analysis was carried out using SAS Studio 3.7 (SAS Institute, Cary, NC, USA) and R version 4.2 (R Foundation for Statistical Computing, Vienna, Austria).

    Results

    Between 2010 and 2019, a total of 5136 patients were diagnosed with MpBC, with a median follow up of 63.44 months (range 2.3–144.89). Of these patients, 3491 (67.9%) underwent upfront surgery and 1645 (32.1%) received NACT. During this time, there was a statistically significant shift in initial treatment strategy among breast cancer patients ( < 0.0001) (Table 1). The proportion of patients undergoing systemic therapy prior to surgery increased from 22.5% in 2010 to 42.1% in 2019. In contrast, the proportion of patients treated with surgery first decreased from 77.5% to 57.9% over the same period (Fig. 1). Table 1Demographic and clinicopathologic characteristics of patients with metaplastic breast cancer undergoing upfront surgery or receiving neoadjuvant chemotherapy, National Cancer Database, 2010–2019Upfront surgeryNeoadjuvant chemotherapyAll-ValueAll3491 (100)1645 (100)5136 (100)Age, years< 0.0001< 50661 (18.93)484 (29.42)1145 (22.29)50–691947 (55.77)905 (55.02)2852 (55.53)≥ 70883 (25.29)256 (15.56)1139 (22.18)Sex0.1617Female3476 (99.57)1642 (99.82)5118 (99.65)Male15 (0.43)3 (0.18)18 (0.35)Year of diagnosis< 0.00012010258 (7.39)75 (4.56)333 (6.48)2011336 (9.62)103 (6.26)439 (8.55)2012357 (10.23)100 (6.08)457 (8.9)2013360 (10.31)107 (6.5)467 (9.09)2014339 (9.71)139 (8.45)478 (9.31)2015346 (9.91)143 (8.69)489 (9.52)2016345 (9.88)166 (10.09)511 (9.95)2017384 (11)196 (11.91)580 (11.29)2018259 (7.42)181 (11)440 (8.57)2019264 (7.56)192 (11.67)456 (8.88)Race0.002African American618 (17.7)359 (21.82)977 (19.02)Asian168 (4.81)74 (4.5)242 (4.71)Caucasian2688 (77)1203 (73.13)3891 (75.76)Other/unknown17 (0.49)9 (0.55)26 (051)Insurance< 0.0001Government1653 (2.98)676 (41.09)2329 (45.35)Private1734 (49.67)905 (55.02)2639 (51.38)Other/unknown104 (2.98)64 (3.89)168 (3.27)Facility type< 0.0001Community cancer program214 (6.13)74 (4.5)288 (5.61)Comprehensive community cancer program1314 (37.64)488 (29.67)1802 (35.09)Academic/research program1110 (31.8)530 (32.22)1640 (31.93)Integrated network cancer program688 (19.71)374 (22.74)1062 (20.68)Other/unknown165 (4.73)179 (10.88)344 (6.7)Charlson–Deyo score0.006702795 (80.06)1381 (83.95)4176 (81.31)1517 (14.81)193 (11.73)710 (13.82)2122 (3.49)53 (3.22)175 (3.41)357 (1.63)18 (1.09)75 (1.46)Grade< 0.0001154 (1.55)6 (0.36)60 (1.17)2332 (9.51)79 (4.8)411 (8)32006 (57.46)803 (48.81)2809 (54.69)Unknown1099 (31.48)757 (46.02)1856 (36.14)Receptor status< 0.0001HR+/HER2−623 (17.85)178 (10.82)801 (15.6)HER2+68 (1.95)73 (4.44)141 (2.75)Triple-negative1952 (55.92)747 (45.41)2699 (52.55)Unknown848 (24.29)647 (39.33)1495 (29.11)Surgery< 0.0001Lumpectomy1729 (49.53)547 (33.25)2276 (44.31)Mastectomy1762 (50.47)1098 (66.75)2860 (55.69)Radiation< 0.0001Breast/chest wall2067 (59.21)1102 (66.99)3169 (61.7)None1335 (38.24)498 (30.27)1833 (35.69)Unknown89 (2.55)45 (2.74)134 (2.61)cT< 0.000111401 (40.13)178 (10.82)1579 (30.74)21687 (48.32)879 (53.43)2566 (49.96)3296 (8.48)386 (23.47)682 (13.28)490 (2.58)198 (12.04)288 (5.61)Unknown17 (0.49)4 (0.24)21 (0.41)cN< 0.000103142 (90)1080 (65.65)4222 (82.2)1269 (7.71)421 (25.59)690 (13.43)238 (1.09)85 (5.17)123 (2.39)313 (0.37)53 (3.22)66 (1.29)Unknown29 (0.83)6 (0.36)35 (0.68)Clinical stage< 0.000111372 (39.3)146 (8.88)1518 (29.56)21888 (54.08)967 (58.78)2855 (55.59)3230 (6.59)532 (32.34)762 (14.84)Unknown1 (0.03)0 (0)1 (0.02)pT< 0.000105 (0.14)41 (2.49)46 (0.9)is1 (0.03)13 (0.79)14 (0.27)11171 (33.54)351 (21.34)1522 (29.63)21783 (51.07)352 (21.4)2135 (41.57)3374 (10.71)226 (13.74)600 (11.68)494 (2.69)97 (5.9)191 (3.72)Unknown63 (1.8)565 (34.35)628 (12.23)pN< 0.000102788 (79.86)764 (46..44)3552 (69.16)1445 (12.75)213 (12.95)658 (12.81)290 (2.58)66 (4.01)156 (3.04)334 (0.97)20 (1.22)54 (1.05)Unknown134 (3.84)582 (35.38)716 (13.94)Pathologic stage< 0.000103 (0.09)36 (2.19)39 (0.76)11131 (32.4)300 (18.24)1431 (27.86)21961 (56.17)508 (30.88)2469 (48.07)3327 (9.37)231 (14.04)558 (10.86)Unknown69 (1.98)570 (34.65)639 (12.44)Pathologic complete responseYes4 (0.11)81 (4.92)85 (1.65)< 0.0001No3487 (99.89)1564 (95.08)5051 (98.35)Data are expressed as (%) hormone receptor, human epidermal growth factor receptor 2Fig. 1Proportion of patients treated for metaplastic breast cancer undergoing upfront surgery or neoadjuvant chemotherapy between 2010 and 2019
    p
    p
    Clinical staging
    Pathologic staging
    n
    HR
    HER2
    Demographic and clinicopathologic characteristics of patients with metaplastic breast cancer undergoing upfront surgery or receiving neoadjuvant chemotherapy, National Cancer Database, 2010–2019
    Data are expressed as n (%)
    HR hormone receptor, HER2 human epidermal growth factor receptor 2
    Proportion of patients treated for metaplastic breast cancer undergoing upfront surgery or neoadjuvant chemotherapy between 2010 and 2019
    Univariate analysis revealed several clinicopathologic differences between MpBC patients undergoing upfront surgery and those receiving NACT (Table 1). Most patients were under the age of 70 years at the time of diagnosis (n = 3997, 77.8%) and had triple-negative disease (n = 2699, 52.55%). Patients receiving NACT were more often younger (p < 0.001), had a higher proportion of HER2+ receptor status (p < 0.001), had a higher proportion of clinical (cN) nodal involvement (p < 0.001), underwent mastectomy at higher proportions (66.75% vs. 50.47%; p < 0.0001), and received breast and chest wall irradiation at higher proportions (66.99% vs. 59.21%; p < 0.0001). pCR was observed in 81 patients (4.92%). Patients undergoing upfront surgery had higher proportions of hormone receptor-positive (HR+)/HER2− and triple-negative receptor status (p < 0.001), had lower clinical (cT) [p < 0.0001] and pathologic (pT) tumor stage (p < 0.0001) and less frequent nodal involvement (pathologic N [pN] stage 0 disease) [p < 0.0001], and underwent lumpectomy at higher proportions (49.53% vs. 33.25%; p < 0.0001).
    Univariate analysis also revealed several demographic differences between MpBC patients undergoing upfront surgery and those receiving NACT (Table 1). The group of patients undergoing upfront surgery included a higher proportion of Caucasian patients (77% vs. 73.13%; p = 0.002) and were more likely to be treated at a Comprehensive Community Cancer Program (37.64% vs. 29.67%; p < 0.0001). The group of patients who received NACT included a higher proportion of non-Hispanic Black patients (21.82% vs. 17.7%; p = 0.002), a higher proportion of patients with a Charlson–Deyo (CD) comorbidity score of 0 (83.95% vs. 80.06%; p = 0.0067), and were more likely to use private insurance (55.02% vs. 49.67%; p < 0.0001).
    The 5-year OS of patients was 76% (95% confidence interval [CI] 0.74–0.77) [electronic supplementary material (ESM) Table 1]. The median OS was not reached. Patients undergoing upfront surgery followed by adjuvant chemotherapy had an increased unadjusted 5-year OS compared with patients receiving NAC (ESM Table 1), and this survival difference persisted in multivariate analysis (hazard ratio [HR] 0.556, 95% CI 0.464–0.667, p < 0.0001) (Fig. 2, Table 2). Higher Charlson–Deyo comorbidity score (HR 1.913, 95% CI 1.127–3.248, p = 0.0163), pathologic tumor stage (pT3: HR 7.447, 95% CI 1.558–35.604, p = 0.0119; pT4: HR 15.199, 95% CI 3.048–75.798, p = 0.0009), and higher pathologic nodal stage (pN1: HR 2.156, 95% CI 1.704–2.728; pN2: HR 2.598, 95% CI 1.719–3.926; pN3: HR 3.928, 95% CI 2.222–6.944, all p < 0.0001) were associated with worse 5-year OS (Table 2). Age ≤ 70 years (age < 50 years: HR 0.684, 95% CI 0.526–0.889, p = 0.0045; age 50–69 years: HR 0.723, 95% CI 0.598–0.875, p = 0.0009), and adjuvant breast and chest wall radiation (HR 0.641, 95% CI 0.536–0.766, p < 0.0001) were associated with improved 5-year OS. No significant survival differences were seen according to sex, race, facility treatment type, tumor grade, receptor status, surgical approach, or clinical stage. Fig. 2Adjusted overall survival of patients with metaplastic breast cancer undergoing upfront surgery or receiving neoadjuvant chemotherapy, National Cancer Database, 2010–2019. Overall survival data were unavailable for 486 patients. Survival analysis was conducted on 4650 patients with available overall survival time and event dataTable 2Adjusted overall survival of patients with metaplastic breast cancer undergoing upfront surgery or receiving neoadjuvant chemotherapy, National Cancer Database, 2010–2019aHazard ratio (95% CI)p-valueTreatment sequenceNeoadjuvant chemotherapyRefUpfront surgery0.556 (0.464–0.667)< 0.0001Age, years< 500.684 (0.526–0.889)0.004550–690.723 (0.598–0.875)0.0009≥70RefSexFemaleRefMale0.718 (0.177–2.911)0.643RaceWhiteRefAfrican American1.003 (0.83–1.213)0.976Asian0.971 (0.648–1.454)0.8858Facility typeIntegrated networkRefCommunity cancer program0.954 (0.665–1.369)0.7977Comprehensive community cancer program1.147 (0.938–1.403)0.1809Academic/research center0.937 (0.76–1.155)0.5428Primary payorPrivateRefGovernment1.255 (1.054–1.493)0.0107Charleson–Deyo0Ref11.189 (0.976–1.449)0.08621.041 (0.699–1.55)0.843731.913 (1.127–3.248)0.0163Grade1Ref21.024 (0.52–2.018)0.944931.029 (0.538–1.972)0.9302Receptor statusTriple-negativeRefHR+/HER2−1.031 (0.859–1.237)0.7414HER2+0.673 (0.433–1.045)0.0775SurgeryMastectomyRefLumpectomy1.091 (0.893–1.335)0.3935Radiation therapyNoneRefBreast/chest wall irradiation0.641 (0.536–0.766)< 0.0001Clinical stagingcT11.256 (0.599–2.636)0.546721.49 (1.026–2.163)0.849331.49 (1.026–2.163)0.03624RefcN01.423 (0.775–2.613)0.255111.087 (0.615–1.92)0.774721.189 (0.64–2.207)0.58353RefClinical stage1Ref21.252 (0.676–2.32)0.474331.543 (0.727–3.276)0.2589Pathologic stagingpT0Refis4.229 (0.519–34.458)0.17812.489 (0.531–11.675)0.247424.352 (0.925–20.475)0.062737.447 (1.558–35.604)0.0119415.199 (3.048–75.798)0.0009pN0Ref12.156 (1.704–2.728)< 0.000122.598 (1.719–3.926)0.000133.928 (2.222–6.944)< 0.0001Pathologic stage0Ref11.67 (0.229–12.176)0.612821.668 (0.231–12.032)0.611931.617 (0.214–12.236)0.6415CI confidence interval, HR hormone receptor, HER2* human epidermal growth factor receptor 2aOverall survival data were unavailable for 486 patients. Survival analysis was conducted on 4650 patients with available overall survival time and event data
    Adjusted overall survival of patients with metaplastic breast cancer undergoing upfront surgery or receiving neoadjuvant chemotherapy, National Cancer Database, 2010–2019. *Overall survival data were unavailable for 486 patients. Survival analysis was conducted on 4650 patients with available overall survival time and event data
    Adjusted overall survival of patients with metaplastic breast cancer undergoing upfront surgery or receiving neoadjuvant chemotherapy, National Cancer Database, 2010–2019a
    CI confidence interval, HR hormone receptor, HER2 human epidermal growth factor receptor 2
    aOverall survival data were unavailable for 486 patients. Survival analysis was conducted on 4650 patients with available overall survival time and event data

    Discussion

    In the current study, we demonstrated that NACT was associated with worse OS in MpBC as compared with upfront surgery followed by adjuvant chemotherapy. The pCR rate was low and there was no increase in the rate of breast conservation following NACT. In contrast, radiation therapy was associated with improved OS.
    MpBC is a rare and aggressive subtype of breast cancer. In a prior study from the NCDB of patients diagnosed with MpBC between 2010 and 2014, those with MpBC were found to have a significantly lower 5-year OS rate of 72.7% compared with 87.5% among those with non-MpBC.3 MpBC has also been shown to have a worse 5-year OS compared with non-metaplastic subtype TNBC.3,4
    The current World Health Organization (WHO) classification of metaplastic carcinoma includes adenosquamous carcinoma, squamous cell carcinoma, spindle cell carcinoma, fibromatosis-like metaplastic carcinoma, and metaplastic carcinoma with mesenchymal differentiation (e.g. chondroid, osseous, rhabdomyoid, or neuroglial elements).5 Only low-grade adenosquamous and low-grade fibromatosis-like carcinoma are considered to have a favorable prognosis without adjuvant systemic therapies.2 Of the other subtypes, metaplastic carcinoma with mesenchymal differentiation appears to have the best 5-year breast cancer-specific survival (BCSS), and squamous MpBC the worst.6-8
    Over 70% of MpBC cases are classified as TNBC, making cytotoxic chemotherapy the primary systemic treatment option.2,3,9 However, despite their triple-negative receptor status, MpBC patients historically have a poor response to chemotherapy, with anywhere from 28 to 46.2% of patients progressing on initial treatment, and some studies suggesting no benefit to chemotherapy at all.6,8,10-13 Previous studies have also shown a relatively low pCR rate for MpBC ranging from 9.8 to 29%.11-15 Our study found a 4.92% pCR rate in this group of patients, which is notably lower than the expected pCR rate of TNBC to traditional NACT (51.2%) or the current standard of care, neoadjuvant chemoimmunotherapy (64.8%), as demonstrated in the KEYNOTE-522 study.16 However, the KEYNOTE-522 study did not specifically evaluate patients with metaplastic TNBC, and data specifically comparing neoadjuvant chemoimmunotherapy with standard NACT in metaplastic TNBC are limited. Nonetheless, regardless of chemotherapeutic regimen, achieving a pCR is associated with improved 5-year OS in both MpBC and other major subtypes of breast cancer.13,17 This highlights the importance of identifying patients who may respond to NACT, or developing novel treatment regimens that can improve response rate.
    In addition to prognostic information, NACT can also offer the opportunity to de-escalate or escalate systemic therapy in the adjuvant setting. A higher residual cancer burden (RCB) score, which serves as a measure of residual cancer, has been associated with worse event-free survival for all breast cancer types, particularly in TNBC.18 Patients with stage I–III TNBC breast cancer treated with NACT with residual disease have been shown to have an improvement in disease-free survival (69.8% vs. 56.1%; HR 0.58, 95% CI 0.39–0.87) when treated with adjuvant capecitabine.19 Additionally, those with residual disease after NACT with germline BRCA1 or BRCA2 mutations have been shown to have an improvement in 3-year disease-free survival (87.5% vs. 80.4%; 95% CI 3.0–11.1) with adjuvant olaparib, once again suggesting that the presence of residual disease is a poor prognostic feature and adjuvant systemic therapy does improve outcomes in these otherwise high-risk patients.20
    Another benefit of NACT is the potential to de-escalate surgery. Our study found that patients receiving NACT underwent mastectomy at a higher rate than patients undergoing upfront surgery (66.75% vs. 50.47%; p < 0.0001). However, regardless of whether patients underwent mastectomy or lumpectomy, surgical approach did not impact OS in our study. This is consistent with previously published data showing no difference in outcomes between breast conservation and mastectomy for MpBC.3,21
    Our study did find improved OS for patients receiving adjuvant breast and chest wall irradiation, a finding consistent with existing literature. A study by Wang et al. utilized the Surveillance, Epidemiology, and End Results (SEER) database to investigate the impact of post-mastectomy radiotherapy (PMRT) on survival outcomes of patients with MpBC treated between 2010 and 2014.22 PMRT was found to significantly enhance the BCSS for patients with both intermediate-risk (T1-2, N1, M0) and high-risk (T1-2, N2-3, M0) disease. A novel machine learning model was recently developed to predict the survival rate for patients with MpBC.23 This model also demonstrated a survival benefit from radiation therapy in patients with stage I–III MpBC undergoing breast-conserving surgery as well as those undergoing mastectomy with T3-4/N2-3M0 disease.
    Treatment sequence had not been extensively studied in MpBC prior to the current study. A 2021 study of 91 patients from a single institution investigated treatment sequence in 91 patients with MpBC, 60 of whom received NACT. The study did not find a significant difference in OS between receipt of NACT versus adjuvant chemotherapy, consistent with findings of the landmark National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 study.24,25 In the current study, patients receiving NACT had a worse 5-year OS, regardless of race, receptor subtype, or other prognostic factors historically associated with worse BCSS outcomes.26 This is likely in large part due to the chemoresistant nature of MpBC evidenced by the low response rate and a higher risk of progression while receiving NACT.
    This study presents certain limitations in its broader applicability to the treatment of MpBC. In addition to the inherent limitations of a retrospective analysis of the NCDB, including the inability to specifically assess disease-specific survival, it lacks the capacity to examine the distinct subtypes of MpBC that may benefit from different treatment approaches. In particular, these data may not apply to the small subset of patients with HER2+ MpBC who would likely still benefit from standard-of-care HER2-targeted therapy in the neoadjuvant and adjuvant settings.27 It is also limited by its ability to evaluate survival in response to neoadjuvant chemoimmunotherapy, which only became standard of care after publication of the KEYNOTE-522 study in 2020 and its US FDA approval in July 2021.16 The potential application of immunotherapy in mTNBC is supported by the high expression of programmed death-ligand 1 (PD-L1)-positive tumor cells and the presence of intratumoral FOXP3+ regulatory T cells observed in metaplastic TNBC tumors, which may render them more susceptible to immune-based treatments and improve the response rate to neoadjuvant systemic therapy.28 Following this rationale, SWOG S1609 (DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors) prospectively enrolled 17 patients with metastatic MpBC and treated them with the dual immune checkpoint inhibitors (ICI) nivolumab and ipilimumab. The trial met its primary endpoint of objective response rate (ORR), with a demonstrated ORR of 18%. Three of the 17 patients with MpBC achieved an objective response, with one complete response and two partial responses.29 Future prospective studies specifically evaluating the response of metaplastic TNBC to neoadjuvant chemoimmunotherapy, as well as the unique treatment needs of the various subtypes of MpBC and incorporating molecular profiling, are needed.30 Based on the data reviewed and available, we recommend that upfront surgery for MpBC leads to superior outcomes, particularly versus NACT, however it is yet to be seen if neoadjuvant chemoimmunotherapy or other novel neoadjuvant approaches in MpBC can significantly improve the otherwise low pCR rate. More data are desperately needed to answer these outstanding questions.
    Despite its limitations, this study represents the largest contemporary analysis of treatment sequencing MpBC. The large sample size enabled robust multivariable modeling and subgroup analysis. Critically, this study fills a gap in the literature by directly comparing NACT with upfront surgery in MpBC.

    Conclusions

    Patients with MpBC who underwent upfront surgery followed by adjuvant chemotherapy had improved OS compared with patients receiving NACT. For patients with resectable MpBC, upfront surgery followed by adjuvant chemotherapy and radiation may offer better outcomes. Further research is needed to clarify the role of immunotherapy in the treatment of MpBC and to identify patients most likely to benefit from systemic therapy. Continued advances in systemic treatment strategies are essential to inform optimal management.

    Supplementary Information

    Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 23 kb)
    Supplementary file1 (DOCX 23 kb)
    AADr. Azka Ali
    Leading Voice

    Dr. Azka Ali

    Hematology & Oncology · Breast Oncology
    Cleveland Clinic Lerner College of Medicine
    drazkaali
    Cleveland, OH